Logo

AstraZeneca and Daiichi Sankyo Present P-Ib (TROPION-Lung02) Trial Results of Datopotamab Deruxtecan (Dato-DXd) for Advanced NSCLC at WCLC 2022

Share this
AstraZeneca and Daiichi Sankyo Present P-Ib (TROPION-Lung02) Trial Results of Datopotamab Deruxtecan (Dato-DXd) for Advanced NSCLC at WCLC 2022

AstraZeneca and Daiichi Sankyo Present P-Ib (TROPION-Lung02) Trial Results of Datopotamab Deruxtecan (Dato-DXd) for Advanced NSCLC at WCLC 2022

Shots:

  • The P-Ib (TROPION-Lung02) trial evaluating datopotamab deruxtecan (4 & 6mg/kg) + pembrolizumab (200mg) with/out Pt CT (carboplatin or cisplatin) in patients with advanced or metastatic NSCLC without actionable genomic alterations
  • The results showed a promising clinical activity along with a tolerable safety profile. In an interim analysis, ORR in the overall population of 37% with a median follow-up of 6.5mos. in patients with datopotamab deruxtecan & pembrolizumab; ORR (41%) with a median follow-up of 4.4 mos. in patients with datopotamab deruxtecan, pembrolizumab & platinum CT, DCR (84%) in both combination therapy
  • In prior untreated patients, ORRs (62% & 50%) in doublet & triplet therapy; PRs (8 & 10); DCR (100% & 90%); grade ≥3 TEAEs (40% & 60%)

Ref: AstraZeneca | Image: AstraZeneca

Click here to­ read the full press release 

Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions